Cisplatin Relocalizes RNA Binding Protein HuR and Enhances the Oncolytic Activity of E4orf6 Deleted Adenovirus

Habiba, Umma; Hossain, Elora; Yanagawa‐Matsuda, Aya; Chowdhury, Abu Faem Mohammad Almas; Tsuda, Masumi; Zaman, Asad-uz; Tanaka, Shinya; Higashino, Fumihiro

doi:10.3390/cancers12040809

Cited by 7 publications

(4 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The synergistic combination of OVs and chemotherapeutic agents can compensate for the current situation wherein the inability of chemotherapeutic agents to induce ICD is the limiting factor. This combination has a significantly improved efficacy in enhancing the stimulation of an anti-tumor immune response compared with single-drug treatment ( Habiba et al, 2020 ). For example, the combination of ONYX-015 and cisplatin significantly improved OS in a tumor xenograft model, showing superior efficacy to cisplatin monotherapy ( Khuri et al, 2000 ).…”

Section: Attempts To Improve the Immunomodulatory Effect Of Chemother...mentioning

confidence: 99%

Combinatorial regimens of chemotherapeutic agents: A new perspective on raising the heat of the tumor immune microenvironment

Liu

Gao

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Harnessing the broad immunostimulatory capabilities of chemotherapy in combination with immune checkpoint inhibitors has improved immunotherapy outcomes in patients with cancer. Certain chemotherapeutic agents can extensively modify the tumor microenvironment (TME), resulting in the reprogramming of local immune responses. Although chemotherapeutic agents with an enhanced generation of potent anti-tumor immune responses have been tested in preclinical animal models and clinical trials, this strategy has not yet shown substantial therapeutic efficacy in selected difficult-to-treat cancer types. In addition, the efficacy of chemotherapeutic agent-based monotherapy in eliciting a long-term anti-tumor immune response is restricted by the immunosuppressive TME. To enhance the immunomodulatory effect of chemotherapy, researchers have made many attempts, mainly focusing on improving the targeted distribution of chemotherapeutic agents and designing combination therapies. Here, we focused on the mechanisms of the anti-tumor immune response to chemotherapeutic agents and enumerated the attempts to advance the use of chemo-immunotherapy. Furthermore, we have listed the important considerations in designing combinations of these drugs to maximize efficacy and improve treatment response rates in patients with cancer.

show abstract

Section: Attempts To Improve the Immunomodulatory Effect Of Chemother...mentioning

confidence: 99%

Combinatorial regimens of chemotherapeutic agents: A new perspective on raising the heat of the tumor immune microenvironment

Liu

Gao

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Dormant cancer cells can be promoted by OVs to cycle into the early S-phase and become vulnerable to chemotherapy [ 113 ]. Additionally, combining chemotherapy with OVT increases apoptosis [ 114 , 115 ].…”

Section: Combination Therapymentioning

confidence: 99%

Oncolytic Viruses for the Treatment of Bladder Cancer: Advances, Challenges, and Prospects

Xia

et al. 2022

JCM

View full text Add to dashboard Cite

Bladder cancer is one of the most prevalent cancers. Despite recent advancements in bladder cancer therapy, new strategies are still required for improving patient outcomes, particularly for those who experienced Bacille Calmette–Guerin failure and those with locally advanced or metastatic bladder cancer. Oncolytic viruses are either naturally occurring or purposefully engineered viruses that have the ability to selectively infect and lyse tumor cells while avoiding harming healthy cells. In light of this, oncolytic viruses serve as a novel and promising immunotherapeutic strategy for bladder cancer. A wide diversity of viruses, including adenoviruses, herpes simplex virus, coxsackievirus, Newcastle disease virus, vesicular stomatitis virus, alphavirus, and vaccinia virus, have been studied in many preclinical and clinical studies for their potential as oncolytic agents for bladder cancer. This review aims to provide an overview of the advances in oncolytic viruses for the treatment of bladder cancer and highlights the challenges and research directions for the future.

show abstract

“…Combination of ECM-degrading GMOVs with chemotherapy overrides the ECM-induced chemo-resistance observed in solid tumors [ 281 ]. Combination therapy of OVs and chemotherapy has been shown to exert synergistic antitumor activities via enhancing tumor cell killing capacity of chemotherapeutic agents, increasing virus proliferation in tumor cells, and invigorating oncolytic activities of OVs [ 282 , 283 ].…”

Section: Combination Therapymentioning

confidence: 99%

Oncolytic Virotherapy in Solid Tumors: The Challenges and Achievements

Jin

Liu

et al. 2021

Cancers

View full text Add to dashboard Cite

Oncolytic virotherapy (OVT) is a promising approach in cancer immunotherapy. Oncolytic viruses (OVs) could be applied in cancer immunotherapy without in-depth knowledge of tumor antigens. The capability of genetic modification makes OVs exciting therapeutic tools with a high potential for manipulation. Improving efficacy, employing immunostimulatory elements, changing the immunosuppressive tumor microenvironment (TME) to inflammatory TME, optimizing their delivery system, and increasing the safety are the main areas of OVs manipulations. Recently, the reciprocal interaction of OVs and TME has become a hot topic for investigators to enhance the efficacy of OVT with less off-target adverse events. Current investigations suggest that the main application of OVT is to provoke the antitumor immune response in the TME, which synergize the effects of other immunotherapies such as immune-checkpoint blockers and adoptive cell therapy. In this review, we focused on the effects of OVs on the TME and antitumor immune responses. Furthermore, OVT challenges, including its moderate efficiency, safety concerns, and delivery strategies, along with recent achievements to overcome challenges, are thoroughly discussed.

show abstract

Cisplatin Relocalizes RNA Binding Protein HuR and Enhances the Oncolytic Activity of E4orf6 Deleted Adenovirus

Cited by 7 publications

References 38 publications

Combinatorial regimens of chemotherapeutic agents: A new perspective on raising the heat of the tumor immune microenvironment

Combinatorial regimens of chemotherapeutic agents: A new perspective on raising the heat of the tumor immune microenvironment

Oncolytic Viruses for the Treatment of Bladder Cancer: Advances, Challenges, and Prospects

Oncolytic Virotherapy in Solid Tumors: The Challenges and Achievements

Contact Info

Product

Resources

About